Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 24, 2023

SELL
$191.51 - $216.16 $130,035 - $146,772
-679 Reduced 23.29%
2,237 $475,000
Q2 2023

Jul 13, 2023

BUY
$187.64 - $206.25 $152,551 - $167,681
813 Added 38.66%
2,916 $561,000
Q1 2023

May 11, 2023

SELL
$127.59 - $203.08 $9,186 - $14,621
-72 Reduced 3.31%
2,103 $426,000
Q4 2022

Feb 08, 2023

SELL
$117.37 - $139.17 $126,172 - $149,607
-1,075 Reduced 33.08%
2,175 $280,000
Q3 2022

Oct 17, 2022

BUY
$135.27 - $180.11 $40,175 - $53,492
297 Added 10.06%
3,250 $444,000
Q2 2022

Jul 13, 2022

BUY
$108.81 - $179.33 $9,901 - $16,319
91 Added 3.18%
2,953 $522,000
Q1 2022

May 12, 2022

BUY
$119.61 - $157.85 $1,913 - $2,525
16 Added 0.56%
2,862 $412,000
Q4 2021

Feb 03, 2022

SELL
$142.57 - $190.86 $78,841 - $105,545
-553 Reduced 16.27%
2,846 $439,000
Q3 2021

Nov 02, 2021

SELL
$142.45 - $169.82 $189,600 - $226,030
-1,331 Reduced 28.14%
3,399 $577,000
Q2 2021

Aug 10, 2021

SELL
$135.08 - $161.1 $1.32 Million - $1.57 Million
-9,748 Reduced 67.33%
4,730 $746,000
Q1 2021

May 07, 2021

SELL
$137.51 - $190.8 $22,689 - $31,482
-165 Reduced 1.13%
14,478 $2.01 Million
Q4 2020

Feb 04, 2021

BUY
$164.63 - $211.93 $2.41 Million - $3.1 Million
14,643 New
14,643 $2.56 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.